Navigation Links
A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders

Purpose

The peroxisome is a cellular organelle that plays an important role in a number of functions, including the beta-oxidation of very long chain fatty acids (VLCFA). Peroxisomal disorders are characterized by impaired, reduced or total absence of peroxisomes in cells, which can result in the accumulation of VLCFAs, such as tetracosanoic and hexacosanoic acids, in plasma. Some variants of these disorders are characterized by the accumulation of phytanic acid.

Up to now, quantification of VLCFA has been done by gas chromatography (GC) or gas chromatography-mass spectrometry (GC-MS). These methods are often time-consuming and quite demanding in terms of sample preparation. Moreover, due to the lack of appropriate standards, quantification of VLCFAs is frequently based only on the calculation of significant ratios such as C 26:0/C 22:0 and C 24:0/C 22:0.

Recently, D.W.Johnson proposed a new procedure for the rapid analysis of VLCFAs based on tandem mass spectrometry(1). This approach targets all the VLCFA forms, i.e. free forms of VLCFA as well as forms that are incorporated into phospholipids and ester forms. The method does not, however, distinguish isobaric forms, because the measurements are done in flow-injection mode.

Overview

This application note describes a method for the quantitation of VLCFAs, using a simple and robust LC/MS/MS hardware configuration. The method includes a chromatographic step and a non-isotopicallylabelled internal standard. The resulting approach has the potential of greater specificity, lower detection limits, and a broader dynamic range than previously suggested strategies, for a wide variety of fatty acids.

Key Features

Sensitive and selective Multiple Reaction Monitoring (MRM) scan function for linear quantitative analysis with wide dynamic range

Patented LINAC collision cell for multi-component analysis at reduced MRM dwell times, maintaining sensitivity and preventing cross talk. This reduces significantly the occurrence of false positive results.

Rugged and reliable triple quadrupole tandem MS system for maximum uptime

Compatibility with the broadest range of ionization sources for the analysis of a wide range of compounds.

Experimental Conditions

Samples were prepared according to the procedure described by Johnson(1) with some modifications. The hardware configuration included an API 3000TM LC/MS/MS System Triple Quadrupole Mass Spectrometer equipped with a TurboIonSpray source. The source operates in positive ion mode at a voltage of +5500 volts and with a turbo gas flow of 8 L/min of air heated at 300 degrees C (nominal heating-gun temperature).

MRM measurements were made using declustering potential (DP) and collision energy (CE) values as optimized automatically by the software for each of the analytes (DP value at 40 V; CE between 30 and 45 eV for the singly charged species measured here).

Chromatography was performed through an Agilent 1100 LC Binary Pump, and separation was accomplished via a Kromasil C8 5μm, 2 x 50 mm column housed in an Agilent 1100 Column Oven at 60C. 3 μL of the reconstituted sample extract were injected into the column using an Agilent 1100 Wellplate Autosampler. All hardware set-up details, solution and reagents requirements, and operating parameters were stored on CD for quick transfer of the proposed methodology.

Results and Discussion

The results of this research study are summarized in the Figures below.

As shown in Figure 1, chromatographic separation and identification of the derivatized pristanic, phytanic, docosanoic, tetracosanoic, and hexacosanoic VLCFAs, and the derivatized internal standards were obtained within 10 minutes of the chromatographic run in gradient mode.

Calibration curves were established for all the compounds in the range of 0.1 to 10 μM with good linearity. As seen in Figure 2, all analytes exhibited correlation coefficients of r = 0.9992 or better (pristanic acid, r = 0.9992; phytanic acid, r = 0.9998; all others r > 0.9999).

Figure 3 shows a typical trace obtained with the proposed protocol on an actual patient sample. Several of the VLCFAs are easily recognized (docosanoic, C 22:0; tetracosanoic, C 24:0; and hexacosanoic, C 26:0). Other signals, which appear through the same MRM transition but at different chromatographic retention times, account for isobaric forms.

The chromatographic peak appearing at 3 minutes through the transition of phytanic acid does not collimate with the peak in Figure 1 appearing at 2.4 minutes and, therefore, must be assigned to an isomer of phytanic acid (C 20:0)

. In Figure 4 the traces shown in Figure 3 are magnified, making it easier to recognize the true phytanic acid, appearing at the expected retention time (RT = 2.4 min.). An isomer of pristanic acid can also be seen, overlapping the phytanic acid peak. The true pristanic acid (indicated by arrow) appears at very low concentration, as expected in a normal sample. Since the measurements included other MRM transitions, signals from several unsaturated-VLCFAs are also evident such as C 22:1 (two adjacent isomers) and C 24:1.

Conclusion

Based on these results, the proposed method proved highly effective in characterizing any single VLCFA due to the chromatographic separation. In addition, the method demonstrated high sensitivity and selectivity for very low physiological concentration of VLCFAs and did not appear susceptible to contamination from external sources. (During sample preparation, detergents used for glassware washing can contaminate samples, resulting in spurious peaks. The chromatographic process used in this method helped to prevent false attributions of VLCFA.) Finally, the method presented in this study was cost-effective, as a result of performing calibration using a homologue as an internal standard rather than using isotopically-labelled standards.

References

1D.W. Johnson, J. Inherit. Metab. Dis.(2000); 23:475-486.

Acknowledgements

Applied Biosystems/MDS SCIEX aknowledges our collaborators, Hlne Belva-Besnet and Bruno Casetta, and Maryse Gravier, Yves Tavet, Isabelle Cuvelier and Didier Olichon from Laboratoire PASTEUR-CERBA, Cergy (France) for providing the method, samples and data for this application note.


'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. prostar RT-PCR Systems for Robust High-Fidelity RNA Amplification
2. Using the TripleMaster PCR System for Robust Amplification of GC-Rich DNA Templates
3. Robust High Throughput RNA Isolation from Blood Samples
4. Detection and Identification of Phosphorylation Sites in Proteins Using LC/MS/MS with Neutral Fragment Loss Mapping
5. The Analysis of Polycyclic Aromatic Hydrocarbons (PAHs) by LC/MS/MS Using an Atmospheric Pressure Photoionization Source
6. HPLC/MS/MS Analysis of Bitter Acids in Hops and Beer
7. Simultaneous Determination of Residues of Approximately 100 Pesticides and Metabolites in Fruit and Vegetables by LC/MS/MS
8. The combination of monolithic columns and modern HPLC/MS/MS instrumentation for high chromatographic throughput and sensitive detection of beta-agonists
9. Determination of Polar Organophosphorus Pesticides in Aqueous Samples by Direct Injection Using HPLC/MS/MS
10. Detection of nitrofurane metabolites in food with HPLC/MS/MS
11. Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... , March 24, 2017  Infectex Ltd., a ... today announced positive results of a Phase 2b-3 clinical ... regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 ... at Sequella, Inc. ( USA ) and ... A total of 140 patients were enrolled in a ...
(Date:3/24/2017)... March 24, 2017 Agenus Inc. (NASDAQ: AGEN), ... antibodies and cancer vaccines, today announced participation at the ...  Annual William Blair and Maidstone Life Sciences conference "Cancer ... in New York, NY . Agenus ... 29 at 9:40 am: Robert B. Stein , ...
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseq™ ... developed with input from industry experts to ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of the world,s ... systems, in terms of costs and resources. However, as the ... of innovative and efficient therapies that demonstrate higher chances of ... cancer treatments, a growing number of patients receiving immuno-oncology therapies ...
Breaking Biology Technology:
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
Breaking Biology News(10 mins):